Andrew Salzman

Andrew L.
Salzman was the founder of Inotek Pharmaceuticals Corp.
(1999) and Beetlebung Pharma Ltd. (2018), where he held the title of President & Chief Executive Officer and Chairman respectively.
Dr. Salzman is also the founder of Radikal Therapeutics, Inc., Tisbury Pharmaceuticals, Inc., Chilmark Labs, Inc. Dr. Salzman's current jobs include Chairman positions at Salzman Capital Ventures Ltd., Respirometics Ltd., and Salzman Lovelace Investments, as well as Chief Scientific Officer at Hinto Energy, Inc. starting in 2023.
Dr. Salzman's former jobs include CEO, Director & Chief Medical Officer at Claritas Pharmaceuticals, Inc., Director-Critical Care Division at Children's Hospital Medical Center of Akron, Director-Drug Development at Lovelace Respiratory Research Institute, and Director at RDD Pharma Ltd. Dr. Salzman's education includes an undergraduate degree from Yale University and a doctorate from Harvard Medical School.